Skip to main content

Table 4 Simulation results for TITE-PK, CRM, and BLRM in Scenarios 1-6

From: Phase I dose-escalation oncology trials with sequential multiple schedules

  Scenario
  1 2 3 4 5 6
Probability of selecting MTD in the targeted toxicity interval
TITE-PK 0.78 0.52 0.75 0.36 0.71 n/a
CRM 0.73 0.61 0.24 0.22 0.79 n/a
BLRM 0.75 0.49 0.64 0.14 0.78 n/a
Probability of selecting MTD in the overdosing interval
TITE-PK 0.11 0.03 n/a 0.06 0.17 0.11
CRM 0.09 0.04 n/a 0.04 0.10 0.14
BLRM 0.06 0.02 n/a 0.04 0.10 0.07
Probability of selecting no combination as MTD
TITE-PK 0.01 0.42 0.00 0.01 0.04 0.87
CRM 0.01 0.36 0.01 0.01 0.03 0.86
BLRM 0.01 0.48 0.01 0.01 0.04 0.92
Mean number of patients enrolled
TITE-PK 24.7 15.4 23.3 27.0 22.8 8.1
CRM 20.9 15.7 20.9 20.8 20.5 8.9
BLRM 23.6 14.9 24.2 24.8 21.9 7.3
Proportion of patients enrolled in the overdosing interval
TITE-PK 0.28 0.15 n/a 0.13 0.27 1.00
CRM 0.05 0.05 n/a 0.01 0.06 1.00
BLRM 0.10 0.08 n/a 0.11 0.11 1.00
Proportion of DLT observed
TITE-PK 0.28 0.38 0.21 0.25 0.30 0.52
CRM 0.18 0.33 0.11 0.15 0.22 0.51
BLRM 0.21 0.35 0.15 0.20 0.24 0.50